Last reviewed · How we verify
Tetanus-diphtheria-pertussis vaccine
The tetanus-diphtheria-pertussis vaccine stimulates the immune system to produce antibodies and cellular immunity against toxins and pathogens from Clostridium tetani, Corynebacterium diphtheriae, and Bordetella pertussis.
The tetanus-diphtheria-pertussis vaccine stimulates the immune system to produce antibodies and cellular immunity against toxins and pathogens from Clostridium tetani, Corynebacterium diphtheriae, and Bordetella pertussis. Used for Prevention of tetanus, Prevention of diphtheria, Prevention of pertussis (whooping cough).
At a glance
| Generic name | Tetanus-diphtheria-pertussis vaccine |
|---|---|
| Sponsor | Tan Tock Seng Hospital |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated toxoids (for tetanus and diphtheria) and acellular pertussis antigens that trigger both humoral and cell-mediated immune responses. These responses generate protective antibodies (particularly IgG) against the bacterial toxins and surface antigens, providing immunity against these three serious bacterial infections. Booster doses maintain protective antibody titers throughout life.
Approved indications
- Prevention of tetanus
- Prevention of diphtheria
- Prevention of pertussis (whooping cough)
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Fatigue or malaise
- Headache
- Myalgia
Key clinical trials
- Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PHASE4)
- A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents) (PHASE1)
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy (PHASE4)
- Safety Monitoring of Boostagen® Vaccine in Thailand
- Long-Term PF-06651600 for the Treatment of Alopecia Areata (PHASE3)
- Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine (PHASE1, PHASE2)
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tetanus-diphtheria-pertussis vaccine CI brief — competitive landscape report
- Tetanus-diphtheria-pertussis vaccine updates RSS · CI watch RSS
- Tan Tock Seng Hospital portfolio CI